Replies to post #148668 on Biotech Values

[genisi]

Per their analysis the “best-case” scenario for change in ADAS-cog for the pooled mild AD subgroups can be from 1.2 to 1.8 points and although stat-sig this change strikes me as clinically insignificant and will surely need another trial as we've said before.